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Abstract
Introduction: To observe the effects of metformin on urinary excretion of MIF, CD74, and podocalyxin in type 2 diabetics, and to explore 
its possible renoprotective mechanisms.
Material and methods: A total of 202 uncontrolled type 2 diabetics, who were previously prescribed sulfonylurea monotherapy (n = 100) 
or sulfonylurea in combination with metformin (n = 102), were enrolled in the study. The amount of macrophage migration inhibitory 
factor (MIF) and CD74 in serum, urinary MIF-to-creatine ratio (UMCR), urinary CD74-to-creatine ratio (UCCR), urinary albumin-to-
creatine ratio (UACR), and urinary podocalyxin-to-creatine ratio (UPCR) were determined. 
Results: Metabolic parameters including fasting blood glucose, postprandial two hours blood glucose, haemoglobin A1c, MIF, and CD74 
in serum were comparable between the two groups. Moreover, metformin add-on therapy showed significantly better efficacy in reducing 
UMCR, UCCR, UPCR, and UACR in comparison with those in the sulfonylurea monotherapy group, respectively. UPCR had a positive 
correlation with UACR, UMCR, and UCCR (r = 0.73, r = 0.69, r = 0.62, P < 0.01), respectively. 
Conclusions: Metformin could present its podocyte-protective capacity in type 2 diabetics, and the underlying mechanisms may be partly 
attributed to its effects in suppressing MIF-CD74 axis-mediated inflammatory cascade response. (Endokrynol Pol 2018; 69 (3): 264–268)
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Streszczenie
Wstęp: Celem pracy było zaobserwowanie efektów działania metforminy na wydalanie MIF, CD74 i podokaliksyny w moczu pacjentów 
z cukrzycą typu 2 oraz zbadanie jej możliwych mechanizmów nefroprotekcyjnych. 
Materiał i metody: W badaniu wzięło udział 202 pacjentów z niewyrównaną cukrzycą typu 2, którym zalecono wcześniej monoterapię 
sulfonylomocznikiem (n = 100) lub sulfonylomocznikiem skojarzonym z metforminą (n = 102). Podczas badania określono ilość czynni-
ka hamującego migrację makrofagów (MIF) i CD74 w surowicy krwi, wskaźnik MIF/kreatynina (urinary MIF to creatinine ratio; UMCR), 
wskaźnik CD74/kreatynina (urinary CD74 to creatinine ratio; UCCR), wskaźnik albumina/kreatynina (urinary albumin to creatinine ratio; 
UACR) oraz wskaźnik podokaliksyna/kreatynina (urinary podocalyxin to creatinine ratio; UPCR).
Wyniki: Parametry metaboliczne, w tym glikemia na czczo, stężenie glukozy we krwi dwie godziny po posiłku, hemoglobina A1c, MIF 
i CD74 w surowicy krwi były porównywalne w obu grupach. Ponadto, terapia z dodatkiem metforminy wykazała znacznie lepszą 
skuteczność w redukowaniu wskaźników UMCR, UCCR, UPCR i UACR w porównaniu z grupą, w której zastosowano monoterapię 
sulfonylomocznikiem. Wskaźnik UPRC wykazywał dodatnią korelację ze wskaźnikami UACR, UMCR i UCCR (odpowiednio: r = 0,73, 
r = 0,69, r = 0,62, p < 0,01).
Wnioski: Metformina może wykazywać zdolność do ochrony podocytów u pacjentów z cukrzycą typu 2, a mechanizmy leżące u pod-
staw tego procesu mogą być częściowo przypisane jej właściwościom hamowania kaskady reakcji zapalnych zależnych od osi MIF-CD74. 
(Endokrynol Pol 2018; 69 (3): 264–268)
Słowa kluczowe: metformina, cukrzyca typu 2, czynnik hamujący migrację makrofagów, CD74, podocyt
Introduction
Apart from metabolic and haemodynamic abnormali-
ties, both enhanced inflammation reaction in local renal 
tissue and podocyte injury participate in the progres-
sion of diabetic nephropathy (DN) [1, 2]. For decades, 
physicians have attempted to present microalbuminuria 
as a clinical marker for DN. However, by the time renal 
dysfunction becomes apparent, podocyte injury has 
already occurred [3]. Emerging evidence has shown 
that podocyte-related proteins, such as podocalyxin [4], 
nephrin, shed in the urine may facilitate earlier detec-
tion of disease and allow closer monitoring of response 
to therapy [5, 6]. 
Macrophage migration inhibitory factor (MIF), a pleio-
tropic inflammatory mediator, is quasi-constitutively 
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expressed by a variety of different cells and tissues, 
including immune and nonimmune cells like podocyte, 
mesangial cells in kidney [7]. It is the only cytokine that is 
stored in the secretary cells and is thus secreted rapidly 
on stimulation of CD74, and it was the first membrane 
receptor for MIF that was discovered; meanwhile, MIF 
and its homolog D-dopachrome tautomerase are the only 
ligands of CD74 [8]. Current research in vitro demon-
strates that MIF exerted proinflammatory effects in 
podocyte via the CD74 receptor under stimulation [9, 10]. 
Metformin, a biguanide drug, is widely prescribed to 
treat high blood glucose in individuals with type 2 dia-
betes mellitus [11].
Despite the long clinical experience with metformin 
and active investigation in this area, its exact mecha-
nisms of action remain unclear. Hence, by virtue of 
analysis the changes of a series of cytokines and po-
docalyxin in urine, the current study aimed to test the 
hypothesis that podocyte injury was associated with the 
inflammatory processes, and the podocyte-protection 
of metformin was related to its inhibiting role of MIF-
-CD74 axis in diabetes mellitus. 
Material and methods
Study design and participants
A total of 202 uncontrolled type 2 diabetics, who were 
previously prescribed sulfonylurea monotherapy (group 
I, n = 100) and sulfonylurea in combination with met-
formin (group II, n = 102) were enrolled in the research. 
According to physician’s prescription, the participants 
received sulfonylureas such as glimepiride (dosage 
range, 2 to 6 mg daily) or gliclazide (dosage range, 80 to 
240 mg daily), or add-on extended-release metformin 
(500 mg/day, up-titrated weekly to a maximum 2000 mg/ 
/day) for 24 weeks. Moreover, all the type 2 diabetics were 
required to maintain their fasting blood glucose range 
from 4.4 to 8.3 mmol/L and to maintain the two-hour 
postprandial blood glucose level at less than 10 mmol/L. 
Consequently, the dosage of each agent was titrated on 
the basis of each study subject’s blood glucose levels. 
Exclusion criteria, including patients who: 1. had 
acute illness or chronic systemic diseases such as hy-
pertension; 2. had primary or secondary renal diseases 
except DN, abnormal serum creatinine; 3. had inflam-
matory diseases (including urinary system infection), 
tumour, or immunity diseases; 4. had acute complications 
or serious chronic complications of diabetes mellitus 
such as ketoacidosis, hyperosmolar coma, and lactic 
acidosis recently; and 5. had statins, aldosterone receptor 
antagonists, angiotensin-converting enzyme inhibitors, 
angiotensin II receptor antagonists in the past two weeks.
Another 100 healthy volunteers were chosen as 
a normal control group. Informed consent was obtained 
from all the participants, meanwhile the study protocol 
was reviewed and accepted by the Ethics Committee of 
Anhui Provincial Hospital, China. The work was carried 
out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki).
Data collection
Clinical data including the age, gender, course of dia-
betes, body mass index (BMI), and blood pressure were 
checked for all subjects, and peripheral venous blood 
samples were obtained. Meanwhile, first morning urine 
(15 ml) was obtained with a sterile cup and preserved at 
–40°C to test the concentrations of albumin, MIF, CD74, 
and podocalyxin. 
Laboratory assays
The concentration of MIF and CD74 in serum and 
urine, as well as urinary podocalyxin were measured 
by enzyme-linked immunosorbent assay (ELISA) 
method. Urinary albumin was assayed using immune 
turbidimetry kits purchased from Northern Biotechno-
logy Research Institute (Beijing, China). Creatine, both 
in urine and serum, was detected by a Hitachi auto-
matic biochemical analyser, blood glucose measured by 
glucose oxidase method, and HbA1c determined by 
high-performance liquid chromatography. The urine 
samples from each patient were assayed in triplicate 
on the same plate. To eliminate the impact of urine 
volume, the levels of urinary albumin, MIF, CD74, and 
podocalyxin were expressed relative to the urinary 
creatinine concentration and referred to as UACR 
(Urinary albumin/UCr: mg/gCr), UMCR (Urinary MIF/ 
/UCr: ng/mgCr), UCCR (Urinary CD74/UCr: ng/mgCr), 
and UPCR (urinary podocalyxin/UCr, ng/mgCr), re-
spectively.
Statistical analysis
Data were expressed as the means ± SD and were 
analysed by Statistical Package for the Social Sciences 
13.0. Some non-normally distributed variables have to 
be compared with parametric tests after log-transfor-
mation. All the parameters between two groups were 
assessed by independent-sample T test. Correlations 
between UPCR and clinical variables were examined by 
spearman correlation. P-values < 0.05 were considered 
to be statistically significant. 
Results
Comparison of biochemical parameters between 
diabetic subjects and control subjects 
As shown in Table I, anthropologic and laboratory 
characteristics including age, gender, BMI, blood pres-
sure, and serum creatinine are comparable among the 
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glucose, HbA1c, MIF, and CD74 in serum between the 
two subgroups (P > 0.05).
Correlations between levels of urinary PCX and 
serum MIF and CD74, urinary MIF, CD74, and 
albumin excretion
As shown in Table II, UPCR has a positive correla-
tion with UACR (r = 0.73), UMCR (r = 0.69), and 
UCCR (r = 0.62), respectively. There is an inferior 
correlation coefficient (r = 0.31) between urinary 
MIF concentration and serum MIF content. No cor-
relations were found, however, between UPCR and 
other clinical variables, such as plasma glucose level 
or blood pressure.
Discussion
Podocyte injury and albuminuria are hallmarks of DN, 
which is the major cause of end-stage renal failure glob-
ally. However, to date, targeted therapies to halt or pre-
vent these complications are currently unavailable [12]. 
Consequently, to identify better strategies for the de-
tection of early stages of DN, numerous biomarkers 
present in urine have been identified that reflect kidney 
injury at specific sites along the nephron. Podocalyxin 
(PCX), initially identified in the glomeruli and known 
as PCX-like protein 1 (PODXL or PCLP1), is the most 
abundant heavily charged sialomucin prominently ex-
pressed by podocyte, whose expression and distribution 
has been correlated with podocyte development [13]. 
Alternatively, urinary podocalyxin has been used for 
reflecting the degree of podocyte injury in multiple 
reports [14, 15]. Our previous research confirmed 
that podocalyxin was barely detectable in the urine 
specimens from normal control subjects, whereas po-
docalyxin shedding occurs in DN [16]. Furthermore, 
urinary podocalyxin excretion was positively corre-
lated with UACR (which is one of the earliest clinical 
manifestation of DN). These findings provide a basis for 
the involvement of podocalyxin in the occurrence and 
Table I. Clinical indexes between sulfonylurea monotherapy 
group and metformin-add on therapy group
Tabela I. Wskaźniki kliniczne między grupą pacjentów, 
u której zastosowano monoterapię sulfonylomocznikiem 
a grupą, u której zastosowano terapię sulfonylomocznikiem 
skojarzonym z metforminą
Variable Normal control Study groups
Sulfonylurea 
monotherapy 
group
Metformin 
add-on therapy 
group
Age (y) 51.77 ± 9.26 56.31 ± 2.80 57.16 ± 3.87
Number  
(Male/Female)
100 (49/51) 100 (49/51) 102 (52/50)
Diabetes 
duration (year)
— 3.34 ± 0.69 3.45 ± 0.51
BMI [kg/m2] 23.74 ± 4.29 24.77 ± 3.36 23.84 ± 4.01
SBP [mmHg] 124.55 ± 12.28 126.11 ± 10.23 124.89 ± 9.46
DBP [mmHg] 74.27 ± 6.84 72.11 ± 7.26 73.18 ± 8.94
SCr [μmol/L] 62.27 ± 9.32 66.12 ± 7.16 64.33 ± 6.29
FBG [mmol/L] 4.89 ± 0.57 6.87 ± 0.69* 6.71 ± 0.73*
PBG [mmol/L] 5.78 ± 0.64 9.71 ± 0.67* 9.46 ± 0.92*
HbA1c (%) 5.21 ± 0.54 7.16 ± 0.73* 7.09 ± 0.66*
Serum MIF-1  
[ng/ml]
2.16 ± 0.30 3.39 ± 0.30* 3.21 ± 0.27*
Serum CD74  
[ng/ml]
11.53 ± 2.36 16.58 ± 4.11* 15.98 ± 4.28*
UACR [mg/gCr] 13.27 ± 2.41 31.14 ± 8.12* 24.33 ± 6.94*△
UMCR [ng/mgCr] 0.51 ± 0.17 2.54 ± 0.29* 2.08 ± 0.23*△
UCCR [ng/mgCr] 0.29 ± 0.03 3.44 ± 0.41* 2.92 ± 0.44*△
UPCR [ng/mgCr] 0.78 ± 0.23 66.82 ± 12.25* 59.76 ± 11.95*△
Values are expressed as  c ± S.
*P < 0.01 versus normal control subjects; P < 0.01 versus sulfonylurea 
monotherapy group
BMI — body mass index; SCr — serum creatinine; FBG — fasting blood 
glucose; PBG — postprandial 2 hours blood glucose; HbA1c — glycated 
haemoglobin A1c; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; UACR — urinary albumin to creatine ratio; UMCR — urinary MIF to 
creatinine ratio; UCCR — urinary CD74 to creatinine ratio; UPCR — urinary 
podocalyxin to creatine ratio
three groups. We found that podocalyxin was barely 
detectable in the urine specimens from normal control 
subjects. Moreover, the levels of FBG, PBG, HbA1c, 
serum MIF, serum CD74, UACR, UMCR, UCCR, and 
UPCR were significantly higher in diabetic patients 
(P < 0.01). 
Comparison of clinical indexes between the  
sulfonylurea monotherapy group and the  
metformin add-on therapy group, respectively
As shown in Table I, compared with the sulfonylurea 
monotherapy group, metformin add-on treatment sig-
nificantly decreased UACR ,UMCR, UCCR, and UPCR 
(P < 0.01, respectively), while there was no significant 
difference in FBG, postprandial two hours blood 
Table II. Correlations between urinary podocalyxin(UPCR) 
and other diabetic characteristics
Tabela II. Współzależności między podokaliksyną w moczu 
(UPCR) i innymi charakterystycznymi cechami dla cukrzycy
UPCR
r P
UMCR 0.692* < 0.01
UCCR 0.736* < 0.01
UACR 0.727* < 0.01
UPCR — urinary podocalyxin to creatine ratio; UACR — urinary albumin to 
creatine ratio; UMCR — urinary MIF to creatinine ratio; UCCR — urinary CD74 
to creatinine ratio
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development of albuminuria, corroborating previous 
research [17].
Macrophage migration inhibitory factor (MIF) is 
a widely expressed pleiotropic cytokine, exhibiting 
a broad range of immune and inflammatory activities. 
It can exert the proinflammatory effects in podocyte via 
the CD74 receptor [9]. In particular, MIF was secreted 
de novo from injured podocyte both in vitro and in 
vivo [18]. The contribution of MIF to renal injury could 
involve promoting inflammatory mediator expression 
and modulation of apoptosis and cell proliferation [19]. 
In the present study, we examined the expression of MIF 
as well as CD74 in type 2 diabetics to clarify the interplay 
between MIF and CD74 concerning DN progression. 
We found that both MIF and CD74 in serum and urine 
specimens were dramatically elevated compared with 
normal control subjects. Moreover, urinary MIF and 
CD74 excretion were positively correlated with the 
grade of podocyte injury. Alternatively, we examined 
whether elevated urinary MIF excretion reflects MIF 
expression within the injured kidney, or from the 
systemic effects of DN. The results showed an inferior 
correlation coefficient between urinary MIF concentra-
tion and serum MIF content (r = 0.31), indicating that 
increased urinary MIF excretion is not simply a reflec-
tion of increased clearance of serum MIF. These findings 
suggest the possibility that the MIF- CD74 axis might 
be involved in the mechanisms of local inflammation 
in diabetic podocytopathy, consistent with a proinflam-
matory state in diabetes [20]. 
Metformin is the most widely prescribed drug 
to treat hyperglycaemia in type 2 diabetics and is 
recommended in conjunction with lifestyle modifica-
tion (i.e. diet, weight control, and physical activity) 
as a first-line oral therapy in the recent guidelines of 
the ADA (American Diabetes Association) and EASD 
(European Association of the Study of Diabetes) [21]. 
The potential benefits of metformin therapy in pa-
tients with type 2 diabetes would extend beyond its 
anti-hyperglycaemic effects through improving glu-
colipid metabolism, decreasing advanced glycation 
end products (AGE), oxidative stress, and endoplasmic 
reticulum (ER) stress [22], inhibiting AMPK/mTOR 
pathway [23], downregulation of phosphorylated p38 
mitogen-activated protein kinase (p-p38MAPK) [24], 
and so on. Zhai et al. [25], from our research group, 
have demonstrated that metformin could ameliorate 
podocyte damage by restoring renal tissue podo-
calyxin expression in type 2 diabetic rats. The ame-
liorative effect of metformin on diabetes-induced 
podocyte loss in experimental diabetic models were 
elaborated. In the present study, following metformin 
add-on therapy, urinary podocalyxin and albumin 
excretion were significantly decreased compared to 
those in the sulfonylurea monotherapy group, which 
is in agreement with our previous investigation from 
experimental diabetic models [25]. On the other hand, 
we found that metformin add-on treatment resulted 
in a significant fall in urinary MIF and CD74 excretion, 
which suggests that anti-inflammation mechanisms 
may be implicated in metformin effects on reducing 
podocyte injury and albuminuria. Glomerular podo-
cytes are capable of synthesising MIF de novo, the 
first cytokine discovered more than 45 years ago [26], 
that could eventually trigger a cell-mediated immune 
reaction, thus promoting a perpetual cycle of injury. 
CD74 is a protein trafficking regulator and a cell 
membrane receptor for MIF [20]. Current studies have 
confirmed the increased CD74 expression in clinical 
and experimental DN and localised glomerular CD74 
to podocyte surface was activated by MIF, leading 
to phosphorylation of extracellular signal–regulated 
kinase 1/2 and p38MAPK [9]. Yao et al. [27] confirmed 
that metformin could alleviate high glucose-induced 
oxidative stress and p-p38MAPK protein expression 
in rat glomerular mesangial cells. According to the 
previous study [9], we may speculate that metformin 
therapy was associated with a substantial reduction in 
urinary MIF and CD74 excretion, which was related 
with suppression of phosphorylation of extracellular 
signal–regulated kinase 1/2 and p38 MAPK pathways, 
thereby downregulating inflammatory cytokines 
such as TNF-related apoptosis-inducing ligand and 
monocyte chemoattractant protein-1 expression, and 
upregulation of podocyte apoptosis. It is worth not-
ing that the results of our study show no difference in 
glycaemic control between the two groups, implying 
that metformin was cable of ameliorating podocyte 
injury and suppression of the local renal inflammation, 
independently of the hypoglycaemic manner. These 
findings may recommend the clinical use of metformin 
in the prevention of DN and improvement of clinical 
outcomes in patients with kidney injury.
However, our data do not identify the perplexity of 
whether MIF participate in the initialisation of diabetic 
podocytopathy or in the progression of DN. The exact 
interplay between MIF, CD74, and other factors concern-
ing podocytopathy remains to be further elaborated in 
detail. Our findings raise the possibility of metformin 
therapy for targeting MIF-CD74 axis-mediated injury in 
DN. Most patients suffering from diabetes might not only 
benefit from therapeutic strategies targeting glycaemic 
control, but also MIF-CD74 axis as well.
Conclusions
In summary, our primary findings demonstrated that 
metformin could present its podocyte-protective capacity 
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in type 2 diabetics, and the underlying mechanisms may 
be partly attributed to its effects in inhibiting MIF-CD74 
axis-mediated inflammatory cascade response. More 
clinical proof concerning the relationship between MIF-
CD74 axis and podocytopathy needs to be elaborated 
in detail.
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